Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

ABC Subtype, TP53 Mutation and BCL2 Overexpression are Associated with a Worse Outcome in Untreated Poor-Risk Young Diffuse Large B-Cell Lymphoma: Results from the Frontline Phase III BIO-DLBCL04 Study of the Fondazione Italiana Linfomi

Blood (2017) 130 (Supplement 1): 4010.

https://doi.org/10.1182/blood.V130.Suppl_1.4010.4010

Published: 2017

Journal Articles

Myc and Bcl2 Overexpression and Traslocation Assessed By Immunohystochemistry (IHC) and FISH: Retrospective Analysis in a Series of De Novo DLBCL Homogeneously Treated with Rituximab-CHOP

Chiara Ciochetto, Maria Stella Scalzo, Barbara Botto, Alessia Castellino, Annalisa Chiappella, MD, Mattia Novo, Maura Nicolosi, Elisa Santambrogio, Federica Cavallo, MD, Paola Ghione, Andrea Evangelista, MSc, Giovannino Ciccone, MD PhD, Roberto Chiarle, MD, Domenico Novero, MD, Umberto Vitolo, MD

Blood (2016) 128 (22): 5305.

https://doi.org/10.1182/blood.V128.22.5305.5305

Published: 2016

Journal Articles

Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts

Blood (2016) 127 (2): 221–232.

https://doi.org/10.1182/blood-2014-12-614503

Published: 2016

Includes: Supplemental data

Journal Articles

De-Novo Diffuse Large B Cell Lymphoma (DLBCL) Treated with Rituximab (R)-CHOP: Definition and Validation of a Prognostic Score Model Based on MYC, BCL2 and BCL6 Expression By Immunohistochemistry (IHC)

Barbara Botto, Alessia Castellino, Annalisa Chiappella, Mattia Novo, Luigi Zattera, Federica Cavallo, Paola Ghione, Andrea Evangelista, Chiara Ciochetto, Giovannino Ciccone, Maria Stella Scalzo, Roberto Chiarle, Domenico Novero, Umberto Vitolo

Blood (2015) 126 (23): 2650.

https://doi.org/10.1182/blood.V126.23.2650.2650

Published: 2015

Journal Articles

The Prognostic Role of Cell of Origin Profile and Myc Expression Assessed By Immunohistochemistry in Young High-Risk Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Results of First-Line Randomized BIO-DLCL04 Trial of Fondazione Italiana Linfomi (FIL)

Annalisa Chiappella, Claudio Agostinelli, Maurizio Martelli, Simona Righi, Andrea Evangelista, Emanuele Angelucci, Monica Balzarotti, Angelo Michele Carella, Manuel Gotti, Domenico Novero, MD, Giuseppe Rossi, MD, Caterina Stelitano, Marco Ladetto, Gianluca Gaidano, Stefano A Pileri, Umberto Vitolo

Blood (2015) 126 (23): 5041.

https://doi.org/10.1182/blood.V126.23.5041.5041

Published: 2015

Journal Articles

GATA-3 Expression in Peripheral T-Cell Lymphomas (PTCL): Identification of a Cut-Off and Prognostic Value in PTCL-NOS Versus Others Hystotypes

Anna Dodero, MD, Francesco Maura, MD, Alessio Pellegrinelli, MD, Antonello Cabras, MD, Annalisa Chiappella, MD, Domenico Novero, MD, Federico Vittone, MD, Francesco Zaja, MD, Stefano Pizzolitto, MD, Cristiana Carniti, PhD, Alessandra Cavane', Martina Pennisi, MD, Umberto Vitolo, MD, Niccolo' Bolli, MD, Paolo Corradini

Blood (2015) 126 (23): 3889.

https://doi.org/10.1182/blood.V126.23.3889.3889

Published: 2015

Journal Articles

The Combination of Weekly Infusion of Rituximab and Bortezomib Is Effective in Relapsed or Refractory Indolent and Mantle Cell Lymphoma: Long-Term Results of Phase II BRIL06 Study of the Fondazione Italiana Linfomi (FIL)

Blood (2015) 126 (23): 2735.

https://doi.org/10.1182/blood.V126.23.2735.2735

Published: 2015

Journal Articles

The Prognostic Value of MYC, BCL2 and BCL6 Overexpression Evaluated By Immunohistochemistry (IHC) in De-Novo Diffuse Large B Cell Lymphoma (DLBCL) Treated with Rituximab-CHOP

Barbara Botto, Domenico Novero, Annalisa Chiappella, Mattia Novo, Alessia Castellino, Chiara Ciochetto, Giovanni Cametti, Andrea Evangelista, Roberto Freilone, Paola Ghione, Marco Ladetto, Paola Riccomagno, Federico Vittone, Giovannino Ciccone, Umberto Vitolo

Blood (2014) 124 (21): 2964.

https://doi.org/10.1182/blood.V124.21.2964.2964

Published: 2014

Journal Articles

Retrospective Analysis of 206 Mantle Cell Lymphoma Patients at Diagnosis: Mantle Cell International Prognostic Index (MIPI) Is a Good Predictor of Death Event In Patients Treated Either with Rituximab-Chemotherapy or Rituximab-High-Dose-Chemotherapy

Blood (2010) 116 (21): 1784.

https://doi.org/10.1182/blood.V116.21.1784.1784

Published: 2010

Journal Articles

Mantle Cell International Prognostic Index (MIPI) Is a Strong Predictor of the Outcome of Mantle Cell Lymphoma (MCL) in the Rituximab (R) Era.

Annalisa Chiappella, Benedetta Puccini, Marianna Rossi, Simone Ferrero, Luca Arcaini, Ernesta Audisio, Ileana Baldi, Carola Boccomini, Barbara Botto, Fabbri Alberto, Chiara Frairia, Roberto Freilone, Marco Ladetto, Domenico Novero, Marco Paulli, Patrizia Pregno, Giorgio Priolo, Luigi Rigacci, Umberto Vitolo

Blood (2009) 114 (22): 2928.

https://doi.org/10.1182/blood.V114.22.2928.2928

Published: 2009

Journal Articles

Activated B-Cell (ABC) Profile Does Not Have An Inferior Outcome Compared to Germinal Center B-Cell (GCB) Profile Determined by Immunohistochemistry Tissue Microarray in Poor Prognosis Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Rituximab and Dose- Dense and High-Dose Chemotherapy (HDC) Plus Autologous Stem Cell Transplantation (ASCT).

Blood (2008) 112 (11): 1139.

https://doi.org/10.1182/blood.V112.11.1139.1139

Published: 2008

Journal Articles

CD38 gene polymorphism and chronic lymphocytic leukemia: a role in transformation to Richter syndrome?

Semra Aydin, Davide Rossi, Luciana Bergui, Giovanni D'Arena, Enza Ferrero, Lisa Bonello, Paola Omedé, Domenico Novero, Fortunato Morabito, Antonino Carbone, Gianluca Gaidano, Fabio Malavasi, Silvia Deaglio

Blood (2008) 111 (12): 5646–5653.

https://doi.org/10.1182/blood-2008-01-129726

Published: 2008

Journal Articles

Rituximab as Adjuvant to Dose-Dense and High Dose Chemotherapy (HDC) with Autologous Stem Cell Transplantation (ASCT) as First Line Treatment in Stage III–IV Diffuse Large B-Cell Lymphoma (DLBCL) at Poor Prognosis: Final Analysis of Phase II GIMURELL Trial.

Blood (2006) 108 (11): 329.

https://doi.org/10.1182/blood.V108.11.329.329

Published: 2006

Journal Articles

Splenic marginal zone lymphoma: a prognostic model for clinical use

Blood (2006) 107 (12): 4643–4649.

https://doi.org/10.1182/blood-2005-11-4659

Published: 2006

Journal Articles

Effect of Adding Rituximab (R) to Induction Treatment and High Dose Chemotherapy (HDC) Prior to Autologous Stem Cell Transplantation (ASCT) as First Line Therapy in Stage III-IV Diffuse Large B-Cell Lymphoma (B-DLCL) at Poor Prognosis.

Blood (2005) 106 (11): 676.

https://doi.org/10.1182/blood.V106.11.676.676

Published: 2005

Journal Articles

Gene Expression Analysis of Peripheral T-Cell Lymphoma Not Otherwise Specified Reveals the Existance of Two Subgroups Related to Different Cellular Counterparts and Recurrent PDGFRA Deregulation.

Pier-Paolo Piccaluga, MD, PhD, Claudio Agostinelli, MD, Simona Zupo, MD, Andrea Califano, PhD, Philip Went, MD, Stefano Ascani, MD, Katia Basso, PhD, Fabio Facchetti, MD, Brunangelo Falini, MD, Manlio Ferrarini, MD, Andrea Gallamini, MD, Ulf Klein, PhD, Domenico Novero, MD, Marco Paulli, MD, Sante Tura, MD, Pier Luigi Zinzani, MD, Michele Baccarani, MD, Riccardo Dalla-Favera, MD, Stefano A. Pileri, MD

Blood (2005) 106 (11): 1217.

https://doi.org/10.1182/blood.V106.11.1217.1217

Published: 2005

Journal Articles

Molecular follow-up in gastric mucosa–associated lymphoid tissue lymphomas: early analysis of the LY03 cooperative trial

Francesco Bertoni, Annarita Conconi, Carlo Capella, Teresio Motta, Roberto Giardini, Maurilio Ponzoni, Ennio Pedrinis, Domenico Novero, Paolo Rinaldi, Giovanni Cazzaniga, Andrea Biondi, Andrew Wotherspoon, Barry William Hancock, Paul Smith, Robert Souhami, Finbarr E. Cotter, Franco Cavalli, Emanuele Zucca

Blood (2002) 99 (7): 2541–2544.

https://doi.org/10.1182/blood.V99.7.2541

Published: 2002

Journal Articles

Idiotype Vaccination in Human Myeloma: Generation of Tumor-Specific Immune Responses After High-Dose Chemotherapy

Massimo Massaia, Paolo Borrione, Silvano Battaglio, Sara Mariani, Eloise Beggiato, Patrizia Napoli, Claudia Voena, Alberto Bianchi, Marta Coscia, Barbara Besostri, Silvia Peola, Thomas Stiefel, Jos Even, Domenico Novero, Mario Boccadoro, Alessandro Pileri

Blood (1999) 94 (2): 673–683.

https://doi.org/10.1182/blood.V94.2.673

Published: 1999

NARROW

ABC Subtype, TP53 Mutation and BCL2 Overexpression are Associated with a Worse Outcome in Untreated Poor-Risk Young Diffuse Large B-Cell Lymphoma: Results from the Frontline Phase III BIO-DLBCL04 Study of the Fondazione Italiana Linfomi

Myc and Bcl2 Overexpression and Traslocation Assessed By Immunohystochemistry (IHC) and FISH: Retrospective Analysis in a Series of De Novo DLBCL Homogeneously Treated with Rituximab-CHOP

Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts

De-Novo Diffuse Large B Cell Lymphoma (DLBCL) Treated with Rituximab (R)-CHOP: Definition and Validation of a Prognostic Score Model Based on MYC, BCL2 and BCL6 Expression By Immunohistochemistry (IHC)

The Prognostic Role of Cell of Origin Profile and Myc Expression Assessed By Immunohistochemistry in Young High-Risk Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Results of First-Line Randomized BIO-DLCL04 Trial of Fondazione Italiana Linfomi (FIL)

GATA-3 Expression in Peripheral T-Cell Lymphomas (PTCL): Identification of a Cut-Off and Prognostic Value in PTCL-NOS Versus Others Hystotypes

The Combination of Weekly Infusion of Rituximab and Bortezomib Is Effective in Relapsed or Refractory Indolent and Mantle Cell Lymphoma: Long-Term Results of Phase II BRIL06 Study of the Fondazione Italiana Linfomi (FIL)

The Prognostic Value of MYC, BCL2 and BCL6 Overexpression Evaluated By Immunohistochemistry (IHC) in De-Novo Diffuse Large B Cell Lymphoma (DLBCL) Treated with Rituximab-CHOP

Retrospective Analysis of 206 Mantle Cell Lymphoma Patients at Diagnosis: Mantle Cell International Prognostic Index (MIPI) Is a Good Predictor of Death Event In Patients Treated Either with Rituximab-Chemotherapy or Rituximab-High-Dose-Chemotherapy

Mantle Cell International Prognostic Index (MIPI) Is a Strong Predictor of the Outcome of Mantle Cell Lymphoma (MCL) in the Rituximab (R) Era.

CD38 gene polymorphism and chronic lymphocytic leukemia: a role in transformation to Richter syndrome?

Rituximab as Adjuvant to Dose-Dense and High Dose Chemotherapy (HDC) with Autologous Stem Cell Transplantation (ASCT) as First Line Treatment in Stage III–IV Diffuse Large B-Cell Lymphoma (DLBCL) at Poor Prognosis: Final Analysis of Phase II GIMURELL Trial.

Splenic marginal zone lymphoma: a prognostic model for clinical use

Effect of Adding Rituximab (R) to Induction Treatment and High Dose Chemotherapy (HDC) Prior to Autologous Stem Cell Transplantation (ASCT) as First Line Therapy in Stage III-IV Diffuse Large B-Cell Lymphoma (B-DLCL) at Poor Prognosis.

Gene Expression Analysis of Peripheral T-Cell Lymphoma Not Otherwise Specified Reveals the Existance of Two Subgroups Related to Different Cellular Counterparts and Recurrent PDGFRA Deregulation.

Molecular follow-up in gastric mucosa–associated lymphoid tissue lymphomas: early analysis of the LY03 cooperative trial

Idiotype Vaccination in Human Myeloma: Generation of Tumor-Specific Immune Responses After High-Dose Chemotherapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only